Jiang Wenbin

Jiang Wenbin, President and CEO of Cytek Biosciences (CTKB), has demonstrated a consistent pattern of selling activity based on SEC Form 4 filings, with no recorded purchases across 32 reported transactions. The filings reveal $357,139 in total sales since August 2025, all executed through derivative transactions coded as "F" (representing dispositions under Rule 16b-6(e)). The most recent sales occurred on March 10, 2026, with three transactions totaling $88,779—comprising $39,829, $32,769, and $16,179 in respective sales. This follows a February 18, 2026, sale of $5,623 and a larger November 18, 2025, series of four sales amounting to $151,555. Earlier transactions in August 2025 accounted for $68,853 across four sales, with individual values ranging from $6,682 to $28,671. The data shows a concentrated selling pattern exclusively in CTKB shares, with no diversification across other companies. While the transactions are relatively modest in size—typically under $40,000—they occur at regular intervals, suggesting a structured approach to reducing holdings. The absence of any buy transactions during this period indicates a one-way disposition trend. The sales are spread across multiple dates rather than clustered, which may reflect prearranged trading plans or periodic liquidity events. All transactions were reported promptly without discrepancies, adhering to SEC disclosure requirements.